Seelos Therapeutics, Inc. (SEEL)
NASDAQ: SEEL · IEX Real-Time Price · USD
0.520
-0.026 (-4.69%)
Jul 22, 2024, 10:10 AM EDT - Market open
Seelos Therapeutics Employees
As of December 31, 2023, Seelos Therapeutics had 16 total employees, including 15 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
16
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$123,375
Profits / Employee
-$1,694,688
Market Cap
1.56M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 16 | 0 | - |
| Dec 31, 2022 | 16 | 0 | - |
| Dec 31, 2021 | 16 | 6 | 60.00% |
| Dec 31, 2020 | 10 | 4 | 66.67% |
| Dec 31, 2019 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Assure Holdings | 95 |
| LogicMark | 27 |
| Azitra | 10 |
| SCWorx | 9 |
| Galmed Pharmaceuticals | 8 |
| Dermata Therapeutics | 8 |
| PainReform | 7 |
| IMAC Holdings | 4 |
SEEL News
- 2 months ago - Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - PRNewsWire
- 2 months ago - Seelos Therapeutics Announces 1-for-8 Reverse Stock Split - PRNewsWire
- 3 months ago - Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations - PRNewsWire
- 4 months ago - Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose) - PRNewsWire
- 6 months ago - Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - PRNewsWire
- 6 months ago - Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002 - PRNewsWire
- 7 months ago - Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024 - PRNewsWire
- 7 months ago - Seelos Therapeutics, Inc. Releases Letter to its Stockholders - PRNewsWire